PERSPECTIVE

Tumor surveillance via the ARF–p53 pathway

Charles J. Sherr¹

Howard Hughes Medical Institute, Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105 USA

The retinoblastoma (*Rb*) and *p53* genes are not essential for completion of the cell division cycle, but disruption of their functions is central to the life history of most, if not all, cancer cells (for review, see Weinberg 1995; Sherr 1996; Levine 1997). Surprisingly, *Rb* and *p53* are themselves regulated by two proteins encoded by a single genetic locus, *INK4a/ARF*, the products of which, *p16^{INK4a}* and *p19^{ARF}*, are also potent tumor suppressors. The role of *p16^{INK4a}* as an inhibitor of cyclin D-dependent kinases has been appreciated since its discovery (Serrano et al. 1993). Now, emerging evidence is providing valuable insights into the molecular circuitry through which *p19^{ARF}* modulates *p53* activity as part of a checkpoint response to oncogenic, hyperproliferative signals.

Regulation of cell cycle progression by pRb and p53

During most of *G*₁ phase of the mammalian cell cycle, *Rb* in its hypophosphorylated form binds to several transcription factors of the E2F family, constraining their activity on some promoters and actively repressing transcription from others (see Dyson 1998). Phosphorylation of *Rb* by cyclin-dependent kinases (cdks) in the mid-to-late *G*₁ phase of the cycle untethers *Rb* from the E2Fs. In turn, this enables the E2Fs to activate a series of target genes, the expression of which is required for cells to enter *S* phase, thereby stimulating proliferation (Fig. 1). The cyclin D-dependent kinases *cdk4* and *cdk6* trigger *Rb* phosphorylation, which is likely completed by cyclin E–*cdk2* as cells approach the *G*₁-to-*S* phase transition. Because induction and assembly of cyclin D-dependent kinases is dependent on mitogenic signaling, cancellation of *Rb*'s growth-suppressive activity is coupled to extracellular stimuli. By inhibiting *cdk4* and *cdk6*, a family of *INK4* proteins can prevent cells with functional *Rb* from entering *S* phase. The prototypic member, *p16^{INK4a}* (Serrano et al. 1993), is distinguished from its close relatives (*p15^{INK4b}*, *p18^{INK4c}*, and *p19^{INK4d}*) in its role as a potent tumor suppressor. Disruption of the *p16^{INK4a}*–cyclin D1/*cdk4*–*Rb* pathway is a common event in human cancer, either resulting from loss of

function of one of the two negative regulators (*p16^{INK4a}* or *Rb*) or from events leading to overexpression of one of the two proto-oncogenes (cyclin D1 or *cdk4*) (for review, see Weinberg 1995; Sherr 1996; Ruas and Peters 1998).

The *p53* protein is a transcription factor that can inhibit cell cycle progression or induce apoptosis in response to stress or DNA damage, and inactivation of *p53* attenuates both of these cellular responses (for review, see Ko and Prives 1996; Levine 1997; Giaccia and Kastan 1998). Elimination of functional *p53* through various mechanisms is the single most common event in human cancer, occurring in over half of all tumors (Hollstein et al. 1994). The *p53* protein is short-lived and expressed at very low levels in normal cells but it is stabilized and accumulates in cells that have sustained genotoxic damage (Fig. 1). Among the gene products induced by *p53* is the cdk inhibitor *p21^{Cip1/Waf1}*, which can effect cell cycle arrest (El-Deiry et al. 1993; Harper et al. 1993; Xiong et al. 1993). Another key target is *Mdm2*, which acts in a feedback loop to limit the action of *p53* (Barak et al. 1993; Wu et al. 1993), both by inhibiting its transactivating activity and by catalyzing its destruction (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997). Mutation of *p53* compromises cell cycle arrest, attenuates apoptosis induced by DNA damage, predisposes cells to drug-induced gene amplification, affects centrosome duplication, and rapidly leads to changes in chromosome number and ploidy (Kastan et al. 1991, 1992; Kuerbitz et al. 1992; Livingstone et al. 1992; Yin et al. 1992; Clarke et al. 1993; Lowe and Ruley 1993; Lowe et al. 1993; Fukusawa et al. 1996; Jacks and Weinberg 1996; Hermeking et al. 1997; Paulovich et al. 1997; Gu-alberto et al. 1998; Lanni and Jacks 1998). The resulting genomic instability greatly increases the probability that *p53*-null cells will evolve toward malignancy.

Cooperation between the *Rb* and *p53* pathways has been amply demonstrated. Classic examples involve oncoproteins encoded by the DNA tumor viruses, which both cancel *Rb* function to drive cells into *S* phase and neutralize *p53* to prevent host cell suicide (for review, see White 1996). Loss of function by *Rb* and related family members can bypass *p53*-mediated *G*₁ arrest (Demers et al. 1994; Slebos et al. 1994), but *Rb* loss induces E2F and *p53*-dependent apoptosis (Lowe and Ruley 1993; Howes et al. 1994; Morgenbesser et al. 1994; Pan and

¹E-MAIL sherr@stjude.org; FAX (901) 495-2381.

Figure 1. ARF checkpoint control. *ARF* responds to proliferative signals that are normally required for cell proliferation. When these signals exceed a critical threshold, the ARF-dependent checkpoint (gray vertical barrel) is activated, and ARF triggers a p53-dependent response that induces growth arrest and/or apoptosis. Signals now known to induce signaling via the ARF–p53 pathway include Myc, E1A, and E2F-1. In principle, ‘upstream’ oncoproteins, such as products of mutated Ras alleles, constitutively activated receptors, or cytoplasmic signal transducing oncoproteins, might also trigger ARF activity via the cyclin D–cdk4–Rb–E2F or Myc-dependent pathways, both of which are normally necessary for S-phase entry. In inhibiting cyclin D-dependent kinases, p16^{INK4a} can dampen the activity of mitogenic signals. E1A is shown to work, at

least in part, by canceling Rb function, although its ability to inhibit p300 contributes to the response by interfering with *mdm2* expression. Again for simplicity, Myc and E2F-1 are only shown to activate p53 via ARF. However, highly overexpressed levels of these proteins can activate p53 in *ARF*-negative cells, albeit with an attenuated efficiency. ARF activation of p53 likely depends on inactivation of some Mdm2-specific function (implied by the unfilled box bracketing the latter two proteins). DNA damage signals (ionizing and UV radiation, hypoxic stress, genotoxic drugs, etc.) access p53 through multiple signaling pathways shown, again for simplicity, as a single DNA damage checkpoint (gray horizontal barrel). Signals through the ARF and DNA damage pathways can synergize in activating p53.

Griep 1994; Qin et al. 1994; Shan et al. 1994; Symonds et al. 1994; Wu and Levine 1994). In short, mutational events that disable the p16^{INK4a}–cyclin D1/cdk4–Rb pathway and enforce cell proliferation are counterbalanced by a p53-dependent apoptotic response that can eliminate incipient cancer cells. The ability of E2F to trigger p53-dependent cell suicide implies that a biochemical connection links their functions. Other cellular oncogenes, such as *myc*, also induce p53-dependent apoptosis (Hermeking and Eick 1994; Wagner et al. 1994). Hence, p53 is not only activated by DNA damage, but it provides an ‘oncogene checkpoint’ function that guards cells against hyperproliferative signals (for review, see Van Dyke 1994; Jacks and Weinberg 1996; White 1996; Levine 1997). This is the setting in which p19^{ARF} plays a key role.

The *INK4a/ARF* locus and tumor suppression

The manner by which a single genetic locus encodes both p16^{INK4a} and p19^{ARF} is unprecedented in mammals (Quelle et al. 1995) (Fig. 2). p16^{INK4a} is encoded by three closely linked exons (designated 1 α , 2, and 3). An RNA segment arising from an alternative first exon (1 β), which maps 13–20 kb upstream in the human, mouse, and rat genomes, is spliced to exon 2, yielding a β transcript that is almost identical in size to the α transcript that encodes p16^{INK4a} (Duro et al. 1995; Mao et al. 1995; Quelle et al. 1995; Stone et al. 1995; Swafford et al. 1997). The initiator codon in exon 1 β is not in frame with sequences encoding p16^{INK4a} in exon 2, so the β transcript specifies a novel polypeptide. In the mouse, this 19-kD protein consists of 65 amino acids encoded by exon 1 β , and 105 amino acids arising from the alternative reading

frame (ARF) of exon 2 (Quelle et al. 1995). The human protein terminates farther upstream in exon 2 and it has a predicted molecular mass of only 14 kD. Mouse p19^{ARF} and human p14^{ARF} are highly basic nuclear proteins that induce G₁- and G₂-phase arrest when introduced into a variety of different cell types (Quelle et al. 1995; Stott et al. 1998). *INK4a/ARF*-null cells are susceptible to ARF-induced arrest, so this activity of p19^{ARF} does not depend upon p16^{INK4a}.

Mutations that inactivate the cdk inhibitory function of p16^{INK4a} occur frequently in a wide spectrum of human cancers (for review, see Ruas and Peters 1998). For example, certain inactivating point mutations impinge on exon 1 α , some of which are inherited in melanoma kindreds (Kamb et al. 1994a,b; Gruis et al. 1995). Although many point mutations in exon 2 of *INK4a* are also predicted to alter p19^{ARF}, those that have been tested experimentally have been found to inactivate p16^{INK4a} without affecting the ability of p19^{ARF} to induce cell cycle arrest. Moreover, the amino-terminal moiety of ARF (amino acids 1–64), encoded entirely by exon 1 β , is sufficient to induce cell cycle arrest when overexpressed (Quelle et al. 1997; Zhang et al. 1998), although tumor-specific point mutations in this domain have not been described (Stone et al. 1995; Ruas and Peters 1998). Together, these data suggest that p16^{INK4a} is disrupted frequently by point mutations in human cancer, but p19^{ARF} is not. However, the common occurrence of homozygous deletions of *INK4a/ARF* in a wide range of human tumors leaves open the possibility that *ARF* plays an independent role as a tumor suppressor (see below).

Functional ablation of *INK4a/ARF* in mice by elimination of exons 2 and 3 (Fig. 2) revealed that derived

Sherr

Figure 2. The *INK4a/ARF* locus. Genomic sequences encoding p16^{INK4a} are defined by completely filled regions within the boxes designating exons 1 α , 2, and 3, whereas the segments of exons 1 β and 2 that encode ARF are defined by shaded areas. Unfilled portions of the exons correspond to noncoding 5' and 3' regions. Splicing between the exons is indicated by the connecting lines, and exons 1 α and 1 β are indicated to have separate promoters ($\rightarrow$). In the mouse genome, the alternative first exons are separated by ~ 13 kb of intervening sequences. Segments of the genes that were disrupted by Serrano et al. (1996) and Kamijo et al. (1997) are designated by horizontal lines below the schematic.

nullizygous animals were highly prone to tumor development (Serrano et al. 1996). Tumors arose early in life, and their appearance was accelerated by irradiation of newborn mice or by their treatment with chemical carcinogens. Intriguingly, mouse embryo fibroblasts (MEFs) explanted from the *INK4a/ARF* knock-out mice did not undergo replicative senescence in culture. Like many established mouse cell lines, but unlike normal primary MEFs, they could be transformed by oncogenic *ras* alleles without a requirement for so-called immortalizing oncogenes such as *myc* or adenovirus *E1A*. MEFs from *p53*-null mice exhibit similar properties (Harvey et al. 1993), and *p53*-inactivating mutations are the most common single events in the spontaneous conversion of MEF strains into continuously growing cell lines (Harvey and Levine 1991). Results with both *INK4a/ARF*-null or *p53*-null MEFs directly contrast with those obtained with normal primary MEF strains, in which introduction of oncogenic *ras* instead provokes a state of growth arrest resembling senescence, associated with accumulation of both *p53* and p16^{INK4a} (Serrano et al. 1997). Initially, it was reasoned that the phenotype observed in *INK4a/ARF*-null mice depended on the loss of p16^{INK4a} function (Serrano et al. 1996). It followed that both p16^{INK4a} and *p53* acted as determinants of cell senescence in MEFs, with the loss of either leading to establishment and immortalization. Release of the senescence block by disruption of p16^{INK4a} or *p53* would be necessary for transformation of mouse fibroblasts by oncogenic *ras* (Serrano et al. 1997; for review, see Weinberg 1997). A persistent ambiguity is whether these mice lack *ARF* function completely. This is likely, because the targeting cassette disrupted the mRNA polyadenylation signals as well as the *INK4a* and *ARF* carboxy-terminal coding sequences (Fig. 2). However, the issue formally remains unresolved, because it is conceivable that a truncated *ARF* protein might somehow arise from undisrupted exon 1 β .

Surprisingly, when pure *ARF*-null mice were created that lacked only the exon 1 β sequences (Fig. 2), their

phenotype was indistinguishable from that attributed previously to p16^{INK4a} disruption (Kamijo et al. 1997). Importantly, functional p16^{INK4a} was expressed in normal tissues of *ARF*-null mice, in cultured MEFs, and in cells from spontaneously arising tumors. Therefore, *ARF* functions as a bona fide tumor suppressor, and the phenotype initially ascribed to *INK4a* loss is instead likely due to *ARF* inactivation. In turn, the phenotypic consequences of p16^{INK4a} loss in mice remain uncertain, and construction of a pure *INK4a* knockout strain is warranted.

The *ARF*-*p53* pathway

A cardinal feature of *ARF*-null MEFs is their capacity to grow as established cell lines and to be transformed by oncogenic *ras* genes alone (Kamijo et al. 1997). Approximately 20% of spontaneously established fibroblast cell lines derived from MEFs of wild-type mice undergo biallelic *ARF* loss. MEF strains that are hemizygous for *ARF* lose their remaining functional *ARF* allele and spontaneously immortalize at a faster rate than wild-type strains. In each case, established MEF cell lines that lacked *ARF* preserved *p53* function, whereas those that retained *ARF* had sustained *p53* mutations. These results suggested that p19^{ARF} and *p53* might function in the same biochemical pathway. Consistent with this hypothesis, cells lacking a functional *p53* gene are resistant to p19^{ARF}-induced cell cycle arrest, implying that *p53* acts downstream of *ARF* (Kamijo et al. 1997). However, *ARF*-null cells exhibit an intact *p53* checkpoint following ionizing or UV irradiation, so p19^{ARF} does not relay signals to *p53* in response to DNA damage (Fig. 1). Loss of *p53* can occur in cancer cells that arise in *ARF*-null mice, again indicating that *ARF* plays a more specialized role in tumor suppression than *p53*, and that selection against *p53* can further contribute to malignancy (Kamijo et al. 1997).

Evidence supporting direct biochemical interactions between p19^{ARF} and *p53* is now in hand. Ectopic *ARF* expression stabilizes *p53* and induces *p53*-responsive genes, *Mdm2* among them. *ARF* can physically interact with *Mdm2*, and its binding blocks both *Mdm2*-induced *p53* degradation and transactivational silencing (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998). The interaction between *Mdm2* and p19^{ARF} depends on the carboxy-terminal half of *Mdm2* and on the *ARF* amino-terminus (i.e., the active exon 1 β -coded segment) (Zhang et al. 1998). Because *Mdm2* binds to *p53* through its amino-terminal domain, *ARF* can enter into ternary complexes with both *Mdm2* and *p53*.

Although human p14^{ARF} appears not to interact with *p53* directly (Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998), there is some evidence that the mouse *ARF* protein can bind to *p53* even in the absence of *Mdm2* (Kamijo et al. 1998). For example, in electrophoretic mobility shift assays performed with purified, activated *p53* and a labeled oligonucleotide containing tandem *p53* consensus DNA-binding sites from the

p21^{Cip1} promoter, addition of recombinant p19^{ARF} retarded the mobility of the p53–oligonucleotide complexes. In these assays, the otherwise latent DNA-binding capability of p53 needed to be activated by antibodies directed to a carboxy-terminal p53 epitope, and p19^{ARF} was unable to substitute for the antibody in activating DNA binding. These observations raise the possibility that interactions between p19^{ARF} and p53 can occur on chromatin, although there is no direct evidence that ARF plays any physiologic role as a p53 coactivator.

ARF requires p53 to induce growth arrest, but the direct physical interactions among p19^{ARF}, p53, and Mdm2 in various binary and ternary complexes suggest that some p53 functions may reciprocally depend on ARF. Overexpression of p19^{ARF} in *ARF*-null NIH-3T3 cells induced expression of a *p21^{Cip1}* promoter-driven reporter gene in a manner that depended on endogenous p53. Paradoxically, ectopic overexpression of wild-type p53 itself in *ARF*-null cells did not activate the reporter, indicating that simple increases in the amount of p53 were insufficient to activate transcription in this setting. p53-Dependent reporter gene expression was restored when subliminal amounts of *ARF* expression vector were reintroduced together with increasing concentrations of p53, so p19^{ARF} can provide some type of activating signal that facilitates p53-dependent transcription (Kamijo et al. 1998). In this respect, the functions of p53 and p19^{ARF} are interdependent.

Zhang and colleagues (1998) reported that ARF accelerated Mdm2 turnover in HeLa cells cotransfected with vectors encoding ARF and Mdm2. They proposed that destabilization of Mdm2 by ARF was the mechanism underlying p53 accumulation. However, experiments by others have yielded conflicting results. The idea that ARF destabilizes Mdm2 seems to be at odds with observations that ARF activation in MEFs induces endogenous Mdm2 to accumulate in a p53-dependent manner (de Stanchina et al. 1998; Kamijo et al. 1998; Zindy et al. 1998). Stott and coworkers (1998) confirmed that in a variety of cell types cotransfected with Mdm2 and p53, introduction of ARF overcame the ability of Mdm2 to induce p53 degradation. However, in the presence or absence of exogenous p53, ARF caused Mdm2 to accumulate. Moreover, coexpression of the E6 protein of human papilloma virus 16, which independently targets p53 for degradation, did not interfere with the ability of ARF to stabilize cotransfected Mdm2. Minimally, it seems reasonable to conclude that ARF can antagonize Mdm2 function through a mechanism that does not depend on increased Mdm2 turnover.

How, then, does ARF stabilize p53? One possibility is that ARF interferes with Mdm2's ability to trigger p53 polyubiquitination. Supporting this idea, Mdm2 seems to induce the appearance of polyubiquitinated forms of p53, which are much less abundant in cells that overexpress p19^{ARF} (Pomerantz et al. 1998). Mdm2 and p19^{ARF} also colocalize in the nucleoli of cells transfected with both genes (Pomerantz et al. 1998). Because p53 degradation depends upon its Mdm2-mediated nuclear export (Roth et al. 1998), ARF could conceivably retain Mdm2–

p53 complexes in the nucleolus, preventing their degradation in the cytoplasm.

Finally, in cells lacking p53, ARF levels are significantly elevated (Quelle et al. 1995; Stott et al. 1998), but reintroduction of wild-type p53 into p53-null MEFs can restore p19^{ARF} to normal levels (Kamijo et al. 1998). Similarly, in human Saos-2 osteosarcoma cells lacking endogenous p53 function, expression of p14^{ARF} was down-regulated when cells were induced to express either tetracycline-regulated or temperature-sensitive p53 (Stott et al. 1998). Therefore, not only can ARF stabilize p53, but ARF expression is in turn controlled by p53 through negative feedback. Again, the underlying mechanism needs to be clarified. Among the possibilities is that the *ARF* gene might be repressed by p53, or the ARF protein could itself be a target of Mdm2-induced turnover.

Oncogenic signals induce ARF

The fact that ARF-null MEFs grow as established cell lines and can be transformed by oncogenic *ras* mimics effects induced by so-called immortalizing oncogenes, like *myc* and *E1A* (Land et al. 1983; Ruley 1983). It therefore seems paradoxical that *myc* and *E1A* are also potent inducers of apoptosis (Askew et al. 1991; White et al. 1991; Evan et al. 1992; Rao et al. 1992), a process aggravated by depriving MEFs of serum survival factors (Evan et al. 1992; Lowe et al. 1993). These contrasting outcomes of *Myc* and *E1A* action—extended life versus accelerated death—can be reconciled by observations that their overexpression provides a strong selective pressure for events that dismantle apoptotic signaling pathways, with *ARF* being a key target.

Overexpression of *Myc*, *E1A*, or *E2F-1* in primary MEFs rapidly induces *ARF* gene expression and leads to p53-dependent apoptosis. However, *ARF*-null and p53-null MEFs resist these effects (de Stanchina et al. 1998; Zindy et al. 1998). Similarly, wild-type or *ARF* hemizygous MEFs that survive *Myc* overexpression generally sustain either p53 mutation or *ARF* loss, but not both, rapidly yielding established cell lines that tolerate supraphysiologic *Myc* levels even in the absence of survival factors (Zindy et al. 1998). *Myc* and *E1A* can induce p53 through both *ARF*-dependent and *ARF*-independent pathways, but much higher levels of oncoprotein expression are required to activate p53 when *ARF* is absent. Under the latter conditions, the p53 response is attenuated and cells resistant to oncogene-induced killing rapidly emerge. Reintroduction of p19^{ARF} into surviving *ARF*-null cells expressing either *Myc* or *E1A* resensitizes them to apoptosis, indicating that the attenuation of death is a direct consequence of *ARF* loss and does not result from other cryptic mutations. Therefore, *Myc*, *E1A*, and *E2F-1* trigger a p53-dependent oncogene checkpoint gated by ARF (Fig. 1). Although the ARF–p53 pathway is not essential for normal proliferation, the checkpoint could provide a fail-safe function during embryonic development. For example, in a model of the developing

murine lens, Rb deficiency triggers apoptosis in a p53-dependent manner (Morgenbesser et al. 1994), but the process is attenuated in lenses from animals lacking *INK4a/ARF* (Pomerantz et al. 1998).

One component of the E1A response involves its ability to activate p300, a coactivator required for p53-dependent *mdm2* transcription (Thomas and White 1998). But the ability of E1A to induce ARF in MEFs is likely mediated by the E2Fs, as E1A mutants that bind p300 but do not interact with Rb are highly defective in this regard (de Stanchina et al. 1998) (Fig. 1). Conditional expression of E2F-1 in Saos-2 cells was followed temporally by increased *ARF* mRNA and protein expression (Bates et al. 1998). Cotransfection experiments indicated that wild-type E2F-1 activated transcription from a minimal *ARF* promoter, whereas an E2F-1 mutant defective in transactivation was devoid of activity. Despite the fact that Myc also induces p19^{ARF} to accumulate very rapidly (Zindy et al. 1998), it is presently unclear whether Myc activates the *ARF* promoter directly.

Cooperation between *myc* and oncogenic *ras* (Land et al. 1983; Rulley 1983) can be viewed to involve the ARF-p53 pathway indirectly. Cultured MEFs achieve replicative immortality by inactivating *ARF* or *p53*, and by promoting cell death, oncogenes such as *E1A* and *myc* provide a strong selective pressure for disabling ARF or p53 function. Because enforced expression of p19^{ARF} arrests wild-type MEFs but does not kill them (Quelle et al. 1995), other functions of Myc and E1A in addition to *ARF* induction are required for this process. The growth promoting properties of Myc and E1A are important because without them, the selection for immortal cells would likely not occur. This is even more obvious in other cell types in which transformation and tumorigenesis strongly depend upon Myc's growth promoting functions even in the absence of *p53* (see, for example, Metz et al. 1995). In turn, Myc and E1A seem to inactivate cellular responses that are normally required for Ras-mediated inhibition of cell proliferation, thereby converting *ras* into a growth-promoting gene (Franza et al. 1986; Hicks et al. 1991; Hirakawa et al. 1991; Lloyd et al. 1997; Serrano et al. 1997). The fact that oncogenic *ras* alone can transform MEFs lacking *ARF* or *p53* argues that their inactivation is key.

Because p19^{ARF} addresses p53 through a pathway that is distinct from those activated by DNA damage (Fig. 1), induction of *ARF* by oncogenes may sensitize cells to the effects of genotoxic drugs that are used to treat cancer. Indeed, MEFs expressing E1A are significantly more sensitive to killing by adriamycin than their normal counterparts, whereas E1A-expressing *ARF*-null MEFs no longer manifest this synergy (de Stanchina et al. 1998). The ability of ARF to sense hyperproliferative stimuli must be important in tumor surveillance, because *ARF* loss strongly predisposes to spontaneous cancer development and accelerates the frequency of tumor induction by irradiation or carcinogens (Serrano et al. 1996; Kamijo et al. 1997). Indeed, in the absence of *ARF* emergence of *p53*-negative tumor cells that are resistant to DNA damaging agents should still occur (Fig. 1).

ARF in human cancer

Much of the experimental work on *ARF* to date has involved murine systems. Senescence (and conversely, immortalization) of human cells is likely to be subject to additional and more stringent controls, particularly in light of our longer life span. Whereas p53 and Rb inactivation can endow human fibroblasts with increased proliferative potential, cells lacking these functions are not immortal, and chromosomal telomere shortening soon limits continued cell proliferation (Bodnar et al. 1998). In contrast, mouse chromosomes have much longer telomeres, and mice lacking telomerase activity must be bred through many generations before the deleterious effects of telomere shortening are manifest (Blasco et al. 1997; Lee et al. 1998).

Despite fundamental differences of this type, *ARF* is likely to function as a tumor suppressor in humans. Certain cancers such as melanomas, biliary tumors, non-small cell lung carcinomas, pancreatic, and esophageal carcinomas frequently sustain *INK4a* point mutations. Other tumor types, however, such as T- and B-cell acute lymphoblastic leukemias, bladder and nasopharyngeal carcinomas, mesotheliomas, anaplastic astrocytomas, and glioblastoma multiforme routinely exhibit *INK4a/ARF* deletions rather than point mutations (Ruas and Peters 1998). Whether or not these homozygous deletions target both *ARF* and *INK4a* or *ARF* alone, their high frequency of occurrence strongly argues that *ARF* loss contributes significantly to human cancer. This makes good sense. If p53 is directly targeted in >50% of human malignancies, then p53-positive tumors have likely sustained epistatic mutations such as *Mdm2* amplification or *ARF* loss. The concept that ARF monitors proliferative signals rather than DNA damage helps to expand our understanding of p53 action and provides a further rationale for *ARF* inactivation through chromosomal deletion in many forms of cancer.

Acknowledgments

I thank Martine F. Roussel, John Cleveland, Gerry Zambetti, Tom Curran, A. Thomas Look, Suzy Baker, Peter McKinnon, Scott W. Lowe, Ron DePinho, Tyler Jacks, Manuel Serrano, and Terry Van Dyke for stimulating and helpful discussions, and Dawn Quelle, Frederique Zindy, Takehiko Kamijo, Jason Weber, and Mangeng Cheng for contributing critical data pertinent to the work from the Sherr and Roussel laboratories. C.J.S. is an investigator of the Howard Hughes Medical Institute and also acknowledges support from the American Lebanese Syrian Associated Charities (ALSAC) of St. Jude Children's Research Hospital.

References

- Askew, D.S., R.A. Ashmun, B.C. Simmons, and J.L. Cleveland. 1991. Constitutive *c-myc* expression in an IL3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. *Oncogene* 6: 1915-1922.

- Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. Mdm2 expression is induced by wild type p53 activity. *EMBO J.* **12**: 461–468.
- Bates, S., A.C. Phillips, P. Clarke, F. Stott, G. Peters, R.L. Ludwig, and K.H. Vousden. 1998. E2F-1 regulation of p14^{ARF} links pRB and p53. *Nature* (in press).
- Blasco, M.A., H.-W. Lee, M.P. Hande, E. Samper, P.M. Lansdorp, R.A. DePinho, and C.W. Greider. 1997. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. *Cell* **91**: 25–34.
- Bodnar, A.G., M. Ouellette, M. Frolkis, S.E. Holt, C.-P. Chiu, G.B. Morin, C.B. Harley, J.B. Shay, S. Lichtsteiner, and W.E. Wright. 1998. Extension of life-span by introduction of telomerase into normal human cells. *Science* **279**: 349–352.
- Clarke, A.R., C.A. Purdie, D.J. Harrison, R.G. Morris, C.C. Bird, M.L. Hooper, and A.H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. *Nature* **362**: 849–852.
- de Stanchina, E., M.E. McCurrach, F. Zindy, S.-Y. Shieh, G. Ferbeyre, A.V. Samuelson, C. Prives, M.F. Roussel, C.J. Sherr, and S.W. Lowe. 1998. E1A signaling to p53 involves the p19^{ARF} tumor suppressor. *Genes & Dev.* **12**: 2435–2443.
- Demers, G.W., S.A. Foster, C.L. Halbert, and D.A. Galloway. 1994. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. *Proc. Natl. Acad. Sci.* **91**: 4382–4386.
- Duro, D., O. Bernard, V. Della Valle, R. Berger, and C.-J. Larsen. 1995. A new type of p16^{INK4a/MTS1} gene transcript expressed in B-cell malignancies. *Oncogene* **11**: 21–29.
- Dyson, N. 1998. The regulation of E2F by pRB-family members. *Genes & Dev.* **12**: 2245–2262.
- El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. *Cell* **75**: 817–825.
- Evan, G.I., A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land, M. Brooks, C.M. Water, L.Z. Penn, and D.C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. *Cell* **69**: 119–128.
- Franza, B.R., K. Maruyama, J.I. Garrels, and H.E. Ruley. 1986. In vitro establishment is not sufficient prerequisite for transformation by activated ras oncogene. *Cell* **44**: 409–418.
- Fukusawa, K., T. Choi, R. Kuriyama, S. Rulong, and G.F. Vande Woude. 1996. Abnormal centrosome amplification in the absence of p53. *Science* **271**: 1744–1747.
- Giaccia, A.J. and M.B. Kastan. 1998. The complexity of p53 modulation: Emerging patterns from divergent signals. *Genes & Dev.* **12**: (this issue).
- Gruis, N.A., P.A. van der Velden, L.A. Sandkuijl, D.E. Prins, J. Weaver-Feldhaus, A. Kamb, W. Bergman, and R. Frants. 1995. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. *Nat. Genet.* **10**: 351–353.
- Gualberto, A., K. Aldape, K. Kozakiewicz, and T.D. Tlsty. 1998. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. *Proc. Natl. Acad. Sci.* **95**: 5166–5171.
- Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* **75**: 805–816.
- Harvey, D.M. and A.J. Levine. 1991. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. *Genes & Dev.* **5**: 2375–2385.
- Harvey, M., A.T. Sands, R.S. Weiss, M.E. Hegi, R.W. Wiseman, P. Pantazis, B.C. Giovanella, M.A. Tainsky, A. Bradley, and L.A. Donehower. 1993. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. *Oncogene* **8**: 2457–2467.
- Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. *Nature* **387**: 296–299.
- Hermeking, H. and D. Eick. 1994. Mediation of c-Myc-induced apoptosis by p53. *Science* **265**: 2091–2093.
- Hermeking, H., C. Lengauer, K. Polyak, T.-C. He, L. Zhang, S. Thiagalingam, K.W. Kinzler, and B. Vogelstein. 1997. 14-3-3 σ is a p53-regulated inhibitor of G2/M progression. *Mol. Cell* **1**: 3–11.
- Hicks, G.C., S.E. Egan, A.H. Greenberg, and M. Mowat. 1991. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. *Mol. Cell. Biol.* **11**: 1344–1352.
- Hirakawa, T. and H.E. Ruley. 1991. Rescue of cells from ras oncogene-induced growth arrest by a second complementing oncogene. *Proc. Natl. Acad. Sci.* **85**: 1519–1523.
- Hollstein, M., K. Rice, M.S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B. Smith-Sorensen, R. Montesano, and C.C. Harris. 1994. Database of p53 gene somatic mutations in human tumors and cell lines. *Nucleic Acids Res.* **22**: 3551–3555.
- Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett.* **420**: 25–27.
- Howes, K.A., N. Ransom, D.S. Papermaster, J.G.H. Lasudry, D.M. Albert, and J.J. Windle. 1994. Apoptosis or retinoblastoma: Alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. *Genes & Dev.* **8**: 1300–1310.
- Jacks, T. and R.A. Weinberg. 1996. Cell-cycle control and its watchman. *Nature* **381**: 643–644.
- Kamb, A., N.A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S.V. Tavtigian, E. Stockert, R.S. Day, III, B.E. Johnson, and M.H. Skolnick. 1994a. A cell cycle regulator involved in genesis of many tumor types. *Science* **264**: 436–440.
- Kamb, A., D. Shattuck-Eidens, R. Eeles, Q. Liu, N.A. Gruis, W. Ding, C. Hussey, T. Tran, Y. Miki, J. Weaver-Feldhaus, M. McClure, J.F. Aitken, D.E. Anderson, W. Bergman, R. Frants, D.E. Goldgar, A. Green, R. MacLennan, N.G. Martin, L.J. Meyer, P. Youl, J.J. Zone, M.H. Skolnick, and L.A. Cannon-Albright. 1994b. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. *Nature Genet.* **8**: 22–26.
- Kamijo, T., F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, G. Grosveld, and C.J. Sherr. 1997. Tumor suppression at the mouse *INK4a* locus mediated by the alternative reading frame product p19^{ARF}. *Cell* **91**: 649–659.
- Kamijo, T., J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. *Proc. Natl. Acad. Sci.* **95**: 8292–8297.
- Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.* **51**: 6304–6311.
- Kastan, M.B., Q. Zhan, W.S. El-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein, and A.J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. *Cell* **71**: 587–597.
- Ko, L.J. and C. Prives. 1996. p53: Puzzle and paradigm. *Genes & Dev.* **10**: 1054–1072.
- Kubbutat, M.H., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stability by Mdm2. *Nature* **387**: 299–303.
- Kuerbitz, S.J., B.S. Plunkett, W.V. Walsh, and M.B. Kastan. 1992.

Sherr

- Wild-type p53 is a cell cycle checkpoint determinant following irradiation. *Proc. Natl. Acad. Sci.* **89**: 7491–7495.
- Land, H., L.F. Parada, and R.A. Weinberg. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. *Nature* **304**: 596–602.
- Lanni, J.S. and T. Jacks. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. *Mol. Cell. Biol.* **18**: 1055–1064.
- Lee, H.-W., M.A. Blasco, G.J. Gottlieb, J.W. Horber, C.W. Greider, and R.A. DePinho. 1998. Essential role of mouse telomerase in highly proliferative organs. *Nature* **392**: 569–574.
- Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. *Cell* **88**: 323–331.
- Livingstone, L.R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T.D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. *Cell* **70**: 923–935.
- Lloyd, A.C., F. Obermuller, S. Staddon, C.F. Barth, M. McMahon, and H. Land. 1997. Cooperating oncogenes converge to regulate cyclin/cdk complexes. *Genes & Dev.* **11**: 663–667.
- Lowe, S.W. and H.E. Ruley. 1993. Stabilization of the p53 tumor suppressor is induced by adenovirus-5 E1A and accompanies apoptosis. *Genes & Dev.* **7**: 535–545.
- Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. *Cell* **74**: 957–966.
- Mao, L., A. Merlo, G. Bedi, G.I. Shapiro, C.D. Edwards, B.J. Rollins, and D. Sidransky. 1995. A novel p16^{INK4a} transcript. *Cancer Res.* **55**: 2995–2997.
- Metz, T., A.W. Harris, and J.M. Adams. 1995. Absence of p53 allows direct immortalization of hematopoietic cells by the *myc* and *raf* oncogenes. *Cell* **82**: 29–36.
- Morgenbesser, S.D., B.O. Williams, T. Jacks, and R.A. DePinho. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. *Nature* **371**: 72–74.
- Pan, H. and A.E. Griep. 1994. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development. *Genes & Dev.* **8**: 1285–1299.
- Paulovich, A.G., D.P. Toczyski, and L.H. Hartwell. 1997. When checkpoints fail. *Cell* **88**: 315–321.
- Pomerantz, J., N. Schreiber-Agus, N.J. Liégeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlov, H.-W. Lee, C. Cordon-Cardo, and R. DePinho. 1998. The *Ink4a* tumor suppressor gene product, p19^{ARF}, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell* **92**: 713–723.
- Qin, X.Q., D.M. Livingston, W.G. Kaelin, Jr., and P.D. Adams. 1994. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. *Proc. Natl. Acad. Sci.* **91**: 10918–10922.
- Quelle, D.E., F. Zindy, R.A. Ashmun, and C.J. Sherr. 1995. Alternative reading frames of the *INK4a* tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell* **83**: 993–1000.
- Quelle, D.E., M. Cheng, R.A. Ashmun, and C.J. Sherr. 1997. Cancer-associated mutations at the *INK4a* locus cancel cell cycle arrest by p16^{INK4a} but not by the alternative reading frame protein p19^{ARF}. *Proc. Natl. Acad. Sci.* **94**: 3436–3440.
- Rao, L., M. Debbas, P. Sabbatini, D. Hockenberry, S. Korsmeyer, and E. White. 1992. The adenovirus E1A proteins induce apoptosis which is inhibited by E1B 19K and Bcl-2 proteins. *Proc. Natl. Acad. Sci.* **89**: 7742–7746.
- Roth, J., M. Döbelstein, D. Freedman, T. Shenk, and A.J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. *EMBO J.* **17**: 554–564.
- Ruas, M. and G. Peters. 1998. The p16^{INK4a}/CDKN2A tumor suppressor and its relatives. *Biochim. Biophys. Acta Rev. Cancer* (in press).
- Ruley, H.E. 1983. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. *Nature* **304**: 602–606.
- Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. *Nature* **366**: 704–707.
- Serrano, M., H.-W. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R.A. DePinho. 1996. Role of the *INK4a* locus in tumor suppression and cell mortality. *Cell* **85**: 27–37.
- Serrano, M., A.W. Lin, M.E. McCurrach, D. Beach, and S.W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16^{INK4a}. *Cell* **88**: 593–602.
- Shan, B. and W.-H. Lee. 1994. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. *Mol. Cell. Biol.* **14**: 8166–8173.
- Sherr, C.J. 1996. Cancer cell cycles. *Science* **274**: 1672–1677.
- Slebos, R.J.C., M.H. Lee, B.S. Plunkett, T.D. Kessis, B.O. Williams, T. Jacks, L. Hedrick, M.B. Kastan, and K.R. Cho. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. *Proc. Natl. Acad. Sci.* **91**: 5320–5324.
- Stone, S., P. Jiang, P. Dayananth, S.V. Tavtigian, H. Katcher, D. Parry, G. Peters, and A. Kamb. 1995. Complex structure and regulation of the p16(MTS1) locus. *Cancer Res.* **55**: 2988–2994.
- Stott, F., S.A. Bates, M. James, B.B. McConnell, M. Starborg, S. Brookes, I. Palmero, E. Hara, K.H. Vousden, and G. Peters. 1998. The alternative product from the human CDKN2A locus, p14^{ARF}, participates in a regulatory feedback loop with p53 and MDM2. *EMBO J.* (in press).
- Swafford, D.S., S.K. Middleton, W.A. Palmisano, K.J. Nikula, J. Tesfaigzi, S.B. Baylin, J.G. Herman, and S.A. Belinsky. 1997. Frequent aberrant methylation of p16^{INK4a} in primary rat lung tumors. *Mol. Cell. Biol.* **17**: 1366–1374.
- Symonds, H., L. Krall, L. Remington, M. Saenz-Robles, S. Lowe, T. Jacks, and T. Van Dyke. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. *Cell* **78**: 703–711.
- Thomas, A. and E. White. 1998. Suppression of the p300-dependent *mdm2* negative-feedback loop induces the p53 apoptotic function. *Genes & Dev.* **12**: 1975–1985.
- Van Dyke, T. 1994. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. *Semin. Cancer Biol.* **5**: 47–60.
- Wagner, A.J., J.M. Kokontis, and N. Hay. 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 waf1/cip1. *Genes & Dev.* **8**: 2817–2830.
- Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. *Cell* **81**: 323–330.
- . 1997. The cat and mouse games that genes, viruses, and cells play. *Cell* **88**: 573–575.
- White, E. 1996. Life, death, and the pursuit of apoptosis. *Genes & Dev.* **10**: 1–15.
- White, E., R. Cipriani, P. Sabbatini, and A. Denton. 1991. The adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. *J. Virol.* **65**: 2968–2978.
- Wu, X. and A.J. Levine. 1994. p53 and E2F-1 cooperate to mediate apoptosis. *Proc. Natl. Acad. Sci.* **91**: 3602–3606.
- Wu, X., J.H. Bayle, D. Olson, and A.J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. *Genes & Dev.* **7**:

ARF tumor suppression

1126–1132.

- Xiong, Y., G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. *Nature* **366**: 701–704.
- Yin, Y., M.A. Tainsky, F.Z. Bischoff, L.C. Strong, and G.M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. *Cell* **70**: 937–948.
- Zhang, Y., Y. Xiong, and W.G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: *ARF-INK4a* locus deletion impairs both the Rb and p53 tumor suppressor pathways. *Cell* **92**: 725–734.
- Zindy, F., C.M. Eischen, D. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. *Genes & Dev.* **12**: 2424–2434.

Tumor surveillance via the ARF–p53 pathway

Charles J. Sherr

Genes Dev. 1998, **12**:

Access the most recent version at doi:[10.1101/gad.12.19.2984](https://doi.org/10.1101/gad.12.19.2984)

References

This article cites 76 articles, 35 of which can be accessed free at:
<http://genesdev.cshlp.org/content/12/19/2984.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).